CN113226325A - 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗 - Google Patents

牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗 Download PDF

Info

Publication number
CN113226325A
CN113226325A CN201980072806.2A CN201980072806A CN113226325A CN 113226325 A CN113226325 A CN 113226325A CN 201980072806 A CN201980072806 A CN 201980072806A CN 113226325 A CN113226325 A CN 113226325A
Authority
CN
China
Prior art keywords
composition
taurolidine
tauramide
effective period
individual patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980072806.2A
Other languages
English (en)
Chinese (zh)
Inventor
B·雷登伯格
R·狄卢西奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of CN113226325A publication Critical patent/CN113226325A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980072806.2A 2018-08-31 2019-09-03 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗 Pending CN113226325A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725650P 2018-08-31 2018-08-31
US62/725650 2018-08-31
PCT/US2019/049266 WO2020047530A1 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Publications (1)

Publication Number Publication Date
CN113226325A true CN113226325A (zh) 2021-08-06

Family

ID=69643283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072806.2A Pending CN113226325A (zh) 2018-08-31 2019-09-03 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗

Country Status (7)

Country Link
EP (1) EP3843747A4 (https=)
JP (2) JP2021535167A (https=)
KR (1) KR20210054544A (https=)
CN (1) CN113226325A (https=)
AU (1) AU2019331913B2 (https=)
CA (1) CA3111100A1 (https=)
WO (1) WO2020047530A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006114A2 (en) * 1997-07-31 1999-02-11 Ed Geistlich Söhne Ag Für Chemische Industrie Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases
CN101111154A (zh) * 2004-12-09 2008-01-23 表达遗传学公司 联合免疫基因疗法和化学疗法用于治疗癌症和过度增生性疾病
US20130089606A1 (en) * 2010-06-01 2013-04-11 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
US7151099B2 (en) * 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
JP5027369B2 (ja) * 1999-12-06 2012-09-19 ガイストリッヒ ファーマ アーゲー 腫瘍を治療する方法
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
CA3018145C (en) * 2016-03-18 2024-09-17 Geistlich Pharma Ag TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
JP2021535163A (ja) * 2018-08-28 2021-12-16 コーメディクス・インコーポレーテッド タウロリジン加水分解産物による神経芽細胞腫治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006114A2 (en) * 1997-07-31 1999-02-11 Ed Geistlich Söhne Ag Für Chemische Industrie Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases
CN101111154A (zh) * 2004-12-09 2008-01-23 表达遗传学公司 联合免疫基因疗法和化学疗法用于治疗癌症和过度增生性疾病
US20130089606A1 (en) * 2010-06-01 2013-04-11 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Also Published As

Publication number Publication date
JP2025128194A (ja) 2025-09-02
JP2021535167A (ja) 2021-12-16
EP3843747A4 (en) 2022-12-28
CA3111100A1 (en) 2020-03-05
AU2019331913B2 (en) 2025-06-26
WO2020047530A1 (en) 2020-03-05
AU2019331913A1 (en) 2021-04-29
KR20210054544A (ko) 2021-05-13
EP3843747A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
JP6076317B2 (ja) 対象において持続的治療薬濃度を実現するための組成物及び方法
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
Naraharisetti et al. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
US20230405132A1 (en) Antitumor pharmaceutical composition and use thereof
JP2021535163A5 (https=)
CN113226325A (zh) 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
US20190381058A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
JP7530351B2 (ja) 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
Zhang et al. polypeptide-based micelles for
TW202023568A (zh) 用於治療癌症之組合療法
KR20250154513A (ko) 췌장암 치료용 약물 조합
Cremers et al. Adriamycin-loaded albumin-heparin conjugate microspheres for intraperitoneal chemotherapy
JPWO2020047113A5 (https=)
JP2023108999A (ja) 抗がん剤含有シート
HK40040830A (en) Combination therapy for treating cancer
WO2001000240A2 (en) Antitumor compound
WO2008033039A1 (en) Cancer treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination